Sieber Justyna, Martin Nicole, Schmidthaler Klara, Gaupmann René, Dehlink Eleonora, Graf Alexandra, Szépfalusi Zsolt, Gruber Saskia
Division of Pediatric Pulmonology, Allergy and Endocrinology, Department of Pediatrics and Adolescent Medicine, Comprehensive Centre of Pediatrics, Medical University of Vienna, 1090 Vienna, Austria.
Institute of Medical Statistics, Centre for Medical Data Science, Medical University of Vienna, 1090 Vienna, Austria.
J Clin Med. 2025 Apr 25;14(9):2979. doi: 10.3390/jcm14092979.
Patients with chronic lung diseases, such as cystic fibrosis, were considered a risk group for a severe course of coronavirus disease 2019 at the beginning of the pandemic. However, mounting evidence suggests that this group may not face an elevated risk for a severe SARS-CoV-2 infection. : Here, we present data on the incidence and clinical course of SARS-CoV-2 infections in a single pediatric CF centre in Austria. Clinical variables were analyzed for their potential impact on disease acquisition and severity. A total of 135 young people with CF were assessed from February 2020 until December 2022. : Eighty-four patients were infected with SARS-CoV-2, out of which nine patients reported re-infection, resulting in 93 SARS-CoV-2 infections. Most infections, 76/93 (82%), occurred during the period of omicron variant predominance. Higher body mass index and respiratory colonization with before the beginning of the pandemic were significantly associated with the risk of acquiring SARS-CoV-2 infection. All patients had an uncomplicated COVID-19 course, regardless of the SARS-CoV-2 variant and COVID-19 vaccine status at infection. The most frequent symptoms were rhinitis (53%), fatigue (49%), cephalea (43%), and fever (38%). Neither oxygen therapy nor hospitalization were needed for any of the patients. Lung function parameters (FEV1, FVC, FEF50, LCI), both in the early post-viral as well as late post-viral stages, were not significantly impacted by SARS-CoV-2 infections. No long-term post-COVID-19 effects were reported. : Our single-centre experience suggests that the course of SARS-CoV-2 infections in children and adolescents with CF is primarily mild and uncomplicated.
在疫情初期，患有慢性肺部疾病（如囊性纤维化）的患者被视为感染2019冠状病毒病后病情严重的风险群体。然而，越来越多的证据表明，这一群体可能不会面临严重的严重急性呼吸综合征冠状病毒2感染风险。在此，我们展示了奥地利一个儿科囊性纤维化中心严重急性呼吸综合征冠状病毒2感染的发病率和临床病程数据。分析了临床变量对疾病感染和严重程度的潜在影响。从2020年2月到2022年12月，共评估了135名患有囊性纤维化的年轻人。84名患者感染了严重急性呼吸综合征冠状病毒2，其中9名患者报告再次感染，导致93次严重急性呼吸综合征冠状病毒2感染。大多数感染（76/93，82%）发生在奥密克戎变异株占主导的时期。大流行开始前较高的体重指数和呼吸道定植与感染严重急性呼吸综合征冠状病毒2的风险显著相关。所有患者的新型冠状病毒肺炎病程均无并发症，无论感染时的严重急性呼吸综合征冠状病毒2变异株和新型冠状病毒肺炎疫苗接种状况如何。最常见的症状是鼻炎（53%）、疲劳（49%）、头痛（43%）和发热（38%）。所有患者均无需吸氧治疗或住院治疗。在病毒感染后的早期和晚期，肺功能参数（第一秒用力呼气容积、用力肺活量、50%用力呼气流量、肺清除指数）均未受到严重急性呼吸综合征冠状病毒2感染的显著影响。未报告新型冠状病毒肺炎后的长期影响。我们的单中心经验表明，患有囊性纤维化的儿童和青少年感染严重急性呼吸综合征冠状病毒2的病程主要为轻度且无并发症。
